Search results
Results from the WOW.Com Content Network
It has been approved as a medication for the treatment of chemotherapy-induced nausea and vomiting (CINV) after clinical trials showed it to have similar or improved efficacy and some improvement in safety over existing drugs for this application. [4] [5] [6] [7]
The newest 5-HT 3 inhibitor, palonosetron (Aloxi), also prevents delayed nausea and vomiting, which can occur during the 2–5 days after treatment. Since some patients have trouble swallowing pills, these drugs are often available by injection , as orally disintegrating tablets , or as transdermal patches .
Palonosetron, sold under the brand name Aloxi, is a medication used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). [2] [4] [5] It is a 5-HT 3 antagonist. [2] [4] [5] Palonosetron is administered intravenously, [6] or as a single oral capsule. [7] It has a longer duration of action than other 5-HT 3 antagonists.
Casopitant (INN Tooltip International Nonproprietary Name), [1]: 208 former tentative trade names Rezonic and Zunrisa , is an NK 1 receptor antagonist which was undergoing research for the treatment of chemotherapy-induced nausea and vomiting. [2] [3] It was under development by GlaxoSmithKline. [2]
A painting from 1681 depicting a person affected by nausea and vomiting. Cancer and nausea are associated in about fifty percent of people affected by cancer. [1] This may be as a result of the cancer itself, or as an effect of the treatment such as chemotherapy, radiation therapy, or other medication such as opiates used for pain relief.
Chemotherapy-induced nausea and vomiting (CINV) are common with many treatments and some forms of cancer. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to successfully manage these symptoms in many people. Effective ...
A lower incidence of grade 2 or higher-grade diarrhea for the crofelemer group was seen than the control group during cycle 2 based on patient outcomes and investigator assessments - (9.0% vs. 33. ...
Aprepitant, sold under the brand name Emend among others, is a medication used to prevent chemotherapy-induced nausea and vomiting and to prevent postoperative nausea and vomiting. [5] It may be used together with ondansetron and dexamethasone. [5] It is taken by mouth [5] or administered by intravenous injection. [3]